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This daily COVID-19 Health Evidence Summary is to signpost DFID and other UK government 
departments to the latest relevant evidence and discourse on COVID-19 to inform and support 
their response. It is a result of 3 hours of work and is not intended to be a comprehensive summary 
of available evidence on COVID-19 but aims to make original documents easily accessible to 
decision makers which, if relevant to them, they should go to before making decisions.   
 
Clinical characteristics and management 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
01.06.2020 COVID-19 
mortality is 
associated 
with pre-
existing 
disease 
burden: a 
cross-
country 
analysis 
Bulletin WHO | 
Article  
 Cross-sectional study of 45 
HICs and 42 non-HICs using 
global burden of disease 
data  
 Whilst in HICs C19 mortality 
was associated with pre-
existing disease burden, no 
association was found 
between disease burdens 
and C19 mortality rate for 
non-HICs 
Mortality, co-
morbidity 
Epidemiology and modelling  
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
03.06.2020 Prevalence of 
asymptomatic 
SARS-CoV-2 
infection: a 
Annals of 
Internal 
 It is likely that 40 to 45% of 
those infected with SARS-
CoV-2 will remain 
asymptomatic – the virus 
Asymptomatic, 
transmission, 
testing 
2 
narrative 
review 
Medicine | 
Review 
may silently spread more 
than previously estimated 
 Asymptomatic persons can 
transmit SARS-CoV-2 and 
perhaps longer than 14 
days 
 Absence of symptoms in 
infected persons might not 
imply absence of harm. 
More research is needed to 
determine the significance 
of subclinical lung changes 
 Testing programmes must 
broaden to include those 
without symptoms 
 Limitation – most data 
under review was from 
cohort studies 
 It remains difficult to 
distinguish between 
asymptomatic and 
presymptomatic persons 
 
Infection Prevention and Control 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
04.06.2020 Social network-
based 
distancing 
strategies to 
flatten the 
COVID-19 
curve in a post-
lockdown world 
Nature 
Human 
Behaviour | 
Article 
 Social, psychological 
and economic 
consequences of 
complete or near-
complete lockdown 
demand more 
moderate contact-
reduction policies 
 The effectiveness of 3 
distancing strategies 
designed to keep the 
curve flat and aid 
compliance post-
lockdown are evaluated 
in this study 
 Strategic social 
network-based 
reduction of contact 
strongly enhances the 
effectiveness of social 
distancing measures 
while keeping risks 
lower 
Social 
distancing, 
behaviour, 
infection control 
3 
03.06.2020 Seroprevalence 
of SARS-CoV-2 
in Hong Kong 
and in 
residents 
evacuated from 
Hubei province 
China: a 
multicohort 
study 
The Lancet 
Microbe | 
Article 
 Control measures 
implemented in Hong 
Kong and Hubei 
province successfully 
restricted the spread of 
SARS-CoV-2 as of May 
2020 
 Relatively low 
seroprevalence 
suggests lack of herd 
immunity and 
susceptibility to a 
resurgence of the 
SARS-CoV-2 epidemic 
if public health 
measures are relaxed 
 Although a small study 
size, provides a 
baseline for public 
health authorities when 
evaluating the effect of 
current and future 
interventions 
Seroprevalence, 
transmission, 
herd immunity 
 
Therapeutics 
Publication 
date 
Title/URL Journal/Article 
type 
Summary             Keywords 
03.06.2020 A randomised trial 
of 
hydroxychloroquine 
as postexposure 
prophylaxis for 
Covid-19 
NEJM | Article 
 A randomised, 
double-blind, 
placebo-controlled 
trial across the US 
and parts of 
Canada testing 
hydroxychloroquine 
as postexposure 
prophylaxis 
 Hydroxychloroquine 
did not prevent 
illness compatible 
with C19 or 
confirmed infection 
when used within 4 
days after high-risk 
or moderate-risk 
exposure to C19  
RCT, 
hydroxychloroqui
ne, prophylaxis 
4 
03.06.2020 Effect of 
convalescent 
plasma therapy on 
time to clinical 
improvement in 
patients with 
severe and life-
threatening 
COVID-19: a 
randomised clinical 
trial 
JAMA | Article 
 In this randomised 
clinical trial of 103 
patients in China 
that was terminated 
early 
(underpowering the 
study), among 
patients with severe 
or life-threatening 
C19, convalescent 
plasma therapy 
added to standard 
treatment did not 
significantly 
improve the time to 
clinical 
improvement within 
28 days 
RCT, 
convalescent 
plasma 
Comments, Editorials, Opinions, Blogs, News 
Publication 
date 
Title/URL Journal | Article type Author(s) 
03.06.2020 Hydroxychloroquine for the 
prevention of COVID-19 – 
searching for evidence 
NEJM | Editorial Marc DuBois 
Julian Sheather 
Catherine R. 
McGowan 
Louisa Baxter 
Rachael 
Cummings 
03.06.2020 Africa’s COVID-19 resilience 
must not lead to complacency 
Chatham House | Comment Dr Knox Chitiyo 
Prof Martin Rupiya 
Pamela Wadi 
03.06.2020 A randomised trial of 
convalescent plasma for COVID-
19 – potentially hopeful signals 
JAMA | Editorial  
5 
03.06.2020 Population serology for SARS-
CoV-2 is essential to regional and 
global preparedness 
The Lancet Microbe | 
Comment 
Huaiyu Tian 
Ottar N Bjornstad 
02.06.2020 Global outbreak research: 
harmony not hegemony 
The Lancet Infectious 
Diseases |Comment 
ISARIC clinical 
characterisation 
group 
02.06.2020 COVID-19 and essential 
pregnant worker policies 
The Lancet Infectious 
Diseases |Correspondence 
Elizabeth S 
McDonald 
02.06.2020 Of viruses, vaccines, and 
variability: qualitative meaning 
matters  
Trends in Cognitive Sciences Valerie F. Reyna 
28.05.2020 Covid-19 in humanitarian 
settings: addressing ethics to 
reduce moral distress 
BMJ | Opinion  
Dashboards & Trackers 
Cases & 
deaths: 
Global 
Cases & 
deaths: 
Regional 
Cases & 
deaths: 
Country 
Living 
evidence & 
policy maps 
Current 
research 
including trials 
  Diagnostics   Treatments   Vaccines 
WHO sitreps WHO 
Africa 
Ghana COVID-
NMA 
WHO   FIND 
SARS-CoV-
2 Test 
Tracker 
  Global 
COVID-19 
Clinical Trial 
Tracker 
  CEPI 
WHO 
dashboard 
African 
Arguments 
Indonesia EPPI 
Centre 
WHO 
International 
Clinical Trials 
Registry 
Platform 
(ICTRP) 
 FIND 
SARS-CoV-
2 
Diagnostics: 
performance 
data 
  US NIH 
registered 
clinical trials 
Vaccine 
Centre 
LSHTM 
Johns 
Hopkins 
University 
European 
CDC 
Nigeria 
CDC 
Norwegian 
Institute of 
Public 
Health 
Cytel  Serology-
based tests 
for COVID-
19 
  Solidarity 
trial 
 COVID-
19 Oxford 
Vaccine 
Trial 
6 
WEF 
  Sierra 
Leone 
 Oxford C19 
Government 
Response 
Tracker 
(OxCGRT) 
US NIH  Our World in 
Data: C19 
Testing 
  COVID-19 
Therapeutics 
Accelerator 
  
Our World in 
Data 
  Singapore  Our World 
in Data: 
C19 Policy 
responses 
COVID-
evidence 
      
Global 5050 
  UK  IFPRI 
COVID-19 
Policy 
Response 
Portal 
Cochrane       
CEBM, 
University of 
Oxford 
  US   Clinicaltrials.gov       
Humanitarian 
Data 
Exchange 
       UKCDR       
Information 
is Beautiful 
              
LSHTM               
HealthMap 
(cases) 
              
The 
Commons 
Project 
              
  
7 
C19 Resource Hubs 
Global  Regional 
& Country 
Academi
c 
journals 
& 
Publisher
s 
Institutes/Centres/Funders/
Other 
Health 
Topics 
  Social 
Sciences 
WHO 
COVID-19 
pandemic  
Africa 
CDC 
Annals of 
Internal 
Medicine 
LSTM Stop TB 
Partnership 
  SSHAP 
WHO risk 
communicati
on 
African 
Union 
BMJ LSHTM 
 
  IDA 
WHO Q&A Nigeria 
CDC 
Bulletin 
of the 
WHO 
ICL MRC Centre for Global 
Infectious Disease Analysis  
Global 
Menstrual 
Collective  
  Disability and 
inclusion 
WHO Global 
research 
GeoPoll: 
SSA 
Cambrid
ge 
Universit
y Press 
ODI SLH: 
Handwashi
ng in low 
resource 
settings 
  Coregroup 
IDDC 
COVID-19 
Solidarity 
Response 
Fund 
Global 
Health 
Network 
Africa 
Cell 
Press 
Johns Hopkins University RBM 
Partnership 
  Ethics, health 
systems & 
COVID-19 
UN African 
Academy 
of 
Sciences 
Cochran
e  
Center for Global 
Development 
    Social 
Development 
Direct C19 
blog series 
UN Women Africa 
Evidence 
Network 
Elsevier CMMID Repository     
UNOCHA OCHA 
Southern 
and 
JAMA 
Network 
Norwegian Institute of 
Public Health 
    
8 
Eastern 
Africa 
COVID-19 
Digest 
UNHCR  South 
African 
Governme
nt 
The 
Lancet 
Oxford Centre for 
Evidence-based Medicine 
    
UNICEF   medRxiv 
and 
bioRxiv 
(Preprint
s) 
 HEART     
UNESCO   NEJM  UKRI     
UN WFP   Oxford 
Universit
y Press 
 Evidence Aid     
GOARN   PLoS  NIH     
EPI-WIN   SAGE 
journals 
IFPRI Resources and 
Analyses of C19 Impact 
    
World Bank   Science  Prevent Epidemics      
Our World in 
Data 
  Springer 
Nature 
      
COVID-19 
Narratives by 
David 
Nabarro 
  SSRN 
(Preprint
s)  
      
Reliefweb   Wiley       
Humanitarian 
OpenStreetM
ap Team 
          
9 
Global 
Partnership 
for 
Sustainable 
Development 
Data 
  
 
      
WorldPop           
Flowminder           
COVID-END           
Premise 
COVID-19 
Global 
Impact Study 
    
  
Online learning & events 
Date Title/URL Online 
learning/event 
Duration Lead 
Available 
now 
Standard precautions: 
Environmental 
cleaning and 
disinfection 
Online course 1 hour WHO 
16.06.2020 Africa beyond COVID-
19 
Virtual event 1h 30 
hours 
ODI 
15.06.2020 Poverty monitoring in 
the context of Covid-
19 
Virtual event 1h 15 ODI 
Available 
now 
COVID-19: Effective 
Nursing in Times of 
Crisis 
Online course 2 weeks – 
2 hours per 
week 
Johns Hopkins School of 
Nursing 
10 
04.06.2020 
12pm ET 
CGD Conversations 
on COVID-19 and 
Development: John 
Nkengasong 
Event   CGD 
Available 
now 
WHO Academy and 
WHO Info mobile 
applications 
Mobile app   WHO 
Available 
now 
COVID-19: 
Pandemics, Modelling 
and Policy 
Online 
learning 
2 weeks | 2 
hours 
weekly 
study 
FutureLearn UNESCO 
UNITWIN Complex 
Systems Digital 
Campus/Open University 
11.5.2020 COVID-19 Contact 
Tracing course 
Online 
learning 
5 hours Johns Hopkins 
Bloomberg School of 
Health 
7-28 May 
2020 
Virtual Evidence 
Weeks 
5 sessions 1h 30 International Initiative for 
Impact Evaluation (3ie) 
Tuesdays at 
1700 CEST 
(Geneva 
time) & 
Thursdays 
0830 CEST 
(Geneva 
time) 
COVID-19 Open 
online brief with Dr 
David Nabarro 
Event 1h 4SD 
30.04.2020 Professor Chris 
Whitty’s Gresham 
lecture on COVID-19 
Event 1h 20 Gresham College 
Available 
now 
Emerging respiratory 
viruses, including 
COVID-19: methods 
for detection, 
prevention, response 
and control 
Online 
learning 
3 hours WHO 
11 
Available 
now 
Responding to 
COVID-19: Real-time 
training for the 
coronavirus disease 
outbreak 
Online 
learning 
Multiple 
self-paced 
course 
WHO 
25 May 
2020 
COVID-19: Tackling 
the Novel Coronavirus 
Online 
learning 
3 weeks | 4 
hours 
weekly 
study 
FutureLearn LSHTM/UK 
PHRST 
Available 
online now 
without 
mentors. 
Updated 
version will 
commence 
early June 
2020 
COVID-19 
Diagnostics and 
Testing 
Online 
learning 
3 weeks | 3 
hours 
weekly 
study 
FutureLearn 
FIND/LSHTM/ASLM 
6 April 2020 COVID-19 Critical 
Care: Understanding 
and Application 
Online 
learning 
5 weeks | 1 
hour 
weekly 
study 
FutureLearn University of 
Edinburgh & Royal 
College of Physicians of 
Edinburgh  
Available 
now 
COVID-19 supporting 
online courses 
Online 
learning 
Multiple 
self-paced 
course 
BMJ Learning 
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Rapid review methodology 
The rapid daily search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa”) OR (“equity” OR “equities”) OR (“poverty”), restricted to 
articles published in the previous 2 to 3 days, in English. This is complemented by a search of the homepage of 
the following high-impact global health journals: The Lancet journals, New England Journal of Medicine, Nature, 
JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ Global Health, the PLoS journals and a Twitter 
search of their Twitter pages. A search also of preprints from bioRxiv and medRxiv. Please note that papers that 
have not been peer-reviewed are highlighted in red. All primary research papers that relate to the primary and 
secondary impacts of the COVID-19 response in LMICs, and disease control and health system responses are 
included. Articles related to tackling the secondary impacts on other sectors are not included. Additional 
commentaries, opinions, and commissioned pieces are selected based on relevance. 
The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
About this report 
This daily COVID-19 health evidence summary (HES) is based on 3 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before 
making decisions. The HES are not intended to replace medical or professional advice and the researcher or the 
K4D consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES 
alone. K4D services are provided by a consortium of leading organisations working in international development, 
led by the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds 
Nuffield Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), 
University of Birmingham International Development Department (IDD) and the University of Manchester 
Humanitarian and Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Department for 
International Development (DFID) and its partners in support of pro-poor programmes. 
It is licensed for non-commercial purposes only. K4D cannot be held responsible for 
errors, omissions or any consequences arising from the use of information contained in 
this health evidence summary. Any views and opinions expressed do not necessarily 
reflect those of DFID, K4D or any other contributing organisation.  
© DFID - Crown copyright 2020. 
 
